Bromide

Bromide

SCHEMBL3854856

O=C(C[n+]1ccsc1)c1ccc(-c2ccccc2)cc1.[Br-]

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.83
KDM4E B2RXH2 3/20 0.68
LMNA P02545 3/20 0.57
KMT2A Q03164 4/20 0.56
MEN1 O00255 2/20 0.56
SMN1; SMN2 Q16637 4/20 0.53
MAPT P10636 2/20 0.53
MITF O75030 1/20 0.53
NR2F2 P24468 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
PTPN1 P18031 1/20 0.46
GSK3B P49841 1/20 0.46
FFAR1 O14842 1/20 0.45
CYP1A2 P05177 1/20 0.45
HIF1A Q16665 1/20 0.45
PABPC1 P11940 2/20 0.44
ATM Q13315 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL122633 0.91 ALDH1A1 (1.00) ALDH1A1KDM4ELMNAKMT2AMEN1
Bromide SCHEMBL7402288 0.91 ALDH1A1 (1.00) ALDH1A1KDM4ELMNAKMT2AMEN1
Bromide SCHEMBL7402285 0.89 ALDH1A1 (0.97) ALDH1A1KDM4ELMNAKMT2AMEN1
SCHEMBL1444452 0.89 ALDH1A1 (0.97) ALDH1A1KDM4ELMNAKMT2AMEN1
Hydrochloric Acid SCHEMBL2776368 0.88 ALDH1A1 (0.94) ALDH1A1KDM4ELMNAKMT2AMEN1
Bromide SCHEMBL28819589 0.88 ALDH1A1 (0.94) ALDH1A1KDM4ELMNAKMT2AMEN1
Pyridine SCHEMBL2361689 0.83 ALDH1A1 (0.83) ALDH1A1KDM4ELMNAKMT2AMEN1
Bromide SCHEMBL3849524 0.82 ALDH1A1 (0.72) ALDH1A1KDM4EKMT2AMEN1MAPT
Bromide SCHEMBL3847335 0.82 ALDH1A1 (0.72) ALDH1A1KDM4EKMT2AMEN1MAPT
Bromide SCHEMBL2947796 0.82 ALDH1A1 (0.72) ALDH1A1KDM4ELMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2085086-A2 Method for treating congestive heart failure or diabetic nephropathy Synvista Therapeutics, Inc. (US) 2009-08-05 EP disclosed
US-20090124674-A1 Method for treating congestive heart failure SYNVISTA THERAPEUTICS, INC. (US) 2009-05-14 US disclosed
US-20090124673-A1 Method for treating diabetic nephropathy SYNVISTA THERAPEUTICS , INC. (US) 2009-05-14 US disclosed
US-7432254-B2 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. (US) 2008-10-07 US disclosed
EP-1353669-B1 METHOD FOR TREATING GLAUCOMA ALTEON INC (US) 2007-08-15 EP disclosed
US-7166625-B2 Method for treating fibrotic diseases and other indications ALTEON, INC. (US) 2007-01-23 US disclosed
EP-1305024-A4 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON INC (US) 2006-03-22 EP disclosed
EP-1353669-A4 METHOD FOR TREATING GLAUCOMA IB ALTEON INC (US) 2005-10-19 EP disclosed
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE SYNVISTA THERAPEUTICS, INC. 2004-11-25 US disclosed
EP-1353669-A1 METHOD FOR TREATING GLAUCOMA IB Alteon, Inc. (US) 2003-10-22 EP disclosed
EP-1305024-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC Alteon, Inc. (US) 2003-05-02 EP disclosed
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID SYNVISTA THERAPEUTICS, INC. 2002-11-28 US disclosed
US-20020160993-A1 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. 2002-10-31 US disclosed
WO-2002053158-A1 METHOD FOR TREATING GLAUCOMA IB ALTEON, INC. (US) 2002-07-11 WO disclosed
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC ALTEON, INC. 2002-06-06 US disclosed
WO-2002007725-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON, INC. (US) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE MMP1, COL1A1, COL2A1 ALDH1A1 175/4885KDM4E 3755/4885LMNA 1024/4885
US-20020160993-A1 Method for treating glaucoma IC CHAT, MYOC, GAP43 ALDH1A1 366/4885KDM4E 4361/4885LMNA 2101/4885
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC MMP1, COL1A1, COL2A1 ALDH1A1 204/4885KDM4E 3863/4885LMNA 1032/4885
US-20090124673-A1 Method for treating diabetic nephropathy REN, SLC5A2, SLC5A1 ALDH1A1 402/4885KDM4E 3627/4885LMNA 1911/4885
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID MMP1, COL1A1, COL2A1 ALDH1A1 261/4885KDM4E 3355/4885LMNA 685/4885
US-20090124674-A1 Method for treating congestive heart failure TNNI3, TNNT2, FABP3 ALDH1A1 448/4885KDM4E 4392/4885LMNA 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.